A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Summary
Third Opinion Trial Synopsis:
The study wants to see if adding a drug called daratumumab to another drug called lenalidomide helps people with a kind of cancer called multiple myeloma. They will test people who have already had treatment and have a test that shows they still have some cancer cells. They will see if the two drugs together can get rid of the cancer cells better than just one of the drugs.
The study wants to see if adding a drug called daratumumab to another drug called lenalidomide helps people with a kind of cancer called multiple myeloma. They will test people who have already had treatment and have a test that shows they still have some cancer cells. They will see if the two drugs together can get rid of the cancer cells better than just one of the drugs.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation sequencing (NGS) at screening, following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation sequencing (NGS) at screening, following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.